Literature DB >> 28480523

Improvement in health-related quality of life after renal sympathetic denervation in real-world hypertensive patients: 12-month outcomes in the Global SYMPLICITY Registry.

Ingrid Kindermann1, Sonja Maria Wedegärtner1, Felix Mahfoud1,2, Joachim Weil3, Nicole Brilakis4, Julia Ukena1, Sebastian Ewen1, Dominik Linz1, Martin Fahy4, Giuseppe Mancia5, Michael Böhm1.   

Abstract

Renal denervation has been shown to reduce blood pressure in patients with uncontrolled hypertension, but less is known about its impact on quality of life. This analysis evaluated 12-month blood pressure and quality of life outcomes in 934 patients from the Global SYMPLICITY Registry who completed the EuroQoL five-dimensions three-level questionnaire (EQ-5D-3L). At baseline, 32% of patients reported anxiety/depression and 48% reported pain/discomfort. At 12 months (n=496), office and 24-hour ambulatory systolic blood pressure were reduced by 13.9±26.6 and 7.7±19.3 mm Hg, respectively, and 8% (P<.001) more patients reported no problems in anxiety/depression. Furthermore, numerically more patients reported no problems in pain/discomfort (4%, P=.08). Perceived health-related quality of life (visual analog scale) improved from baseline to 12 months (68±18 vs 73±17, P<.001), and the improvement was largest among patients with severe anxiety/depression at baseline (50±24 vs 64±22, P=.005 [n=32]). In this analysis, renal denervation was associated with a significant improvement in health-related quality of life, particularly anxiety/depression. ©2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  EQ-5D; anxiety; depression; quality of life; renal sympathetic denervation

Mesh:

Year:  2017        PMID: 28480523      PMCID: PMC8031037          DOI: 10.1111/jch.13007

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  40 in total

1.  Blood pressure responses to renal denervation precede and are independent of the sympathetic and baroreflex effects.

Authors:  Guido Grassi; Gino Seravalle; Gianmaria Brambilla; Daniela Trabattoni; Cesare Cuspidi; Rocco Corso; Federico Pieruzzi; Simonetta Genovesi; Andrea Stella; Rita Facchetti; Domenico Spaziani; Antonio Bartorelli; Giuseppe Mancia
Journal:  Hypertension       Date:  2015-03-30       Impact factor: 10.190

2.  Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial.

Authors:  Michel Azizi; Marc Sapoval; Philippe Gosse; Matthieu Monge; Guillaume Bobrie; Pascal Delsart; Marco Midulla; Claire Mounier-Véhier; Pierre-Yves Courand; Pierre Lantelme; Thierry Denolle; Caroline Dourmap-Collas; Hervé Trillaud; Helena Pereira; Pierre-François Plouin; Gilles Chatellier
Journal:  Lancet       Date:  2015-01-26       Impact factor: 79.321

3.  Reflex vasopressin and renin modulation by cardiac receptors in humans.

Authors:  C Giannattasio; A Del Bo; B M Cattaneo; C Cuspidi; E Gronda; M Frigerio; M Mangiavacchi; M Marabini; C De Vita; G Grassi
Journal:  Hypertension       Date:  1993-04       Impact factor: 10.190

Review 4.  Translational medicine: the antihypertensive effect of renal denervation.

Authors:  Gerald F DiBona; Murray Esler
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-12-02       Impact factor: 3.619

5.  Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease.

Authors:  G Coteur; B Feagan; D L Keininger; M Kosinski
Journal:  Aliment Pharmacol Ther       Date:  2009-05-01       Impact factor: 8.171

6.  Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial.

Authors:  Murray D Esler; Michael Böhm; Horst Sievert; Christian L Rump; Roland E Schmieder; Henry Krum; Felix Mahfoud; Markus P Schlaich
Journal:  Eur Heart J       Date:  2014-06-04       Impact factor: 29.983

7.  A controlled trial of renal denervation for resistant hypertension.

Authors:  Deepak L Bhatt; David E Kandzari; William W O'Neill; Ralph D'Agostino; John M Flack; Barry T Katzen; Martin B Leon; Minglei Liu; Laura Mauri; Manuela Negoita; Sidney A Cohen; Suzanne Oparil; Krishna Rocha-Singh; Raymond R Townsend; George L Bakris
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

8.  Sympatho-renal axis in chronic disease.

Authors:  Paul A Sobotka; Felix Mahfoud; Markus P Schlaich; Uta C Hoppe; Michael Böhm; Henry Krum
Journal:  Clin Res Cardiol       Date:  2011-06-19       Impact factor: 5.460

Review 9.  EQ-5D in skin conditions: an assessment of validity and responsiveness.

Authors:  Yaling Yang; John Brazier; Louise Longworth
Journal:  Eur J Health Econ       Date:  2014-10-31

10.  The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference.

Authors:  Claire M Nolan; Louise Longworth; Joanne Lord; Jane L Canavan; Sarah E Jones; Samantha S C Kon; William D-C Man
Journal:  Thorax       Date:  2016-03-30       Impact factor: 9.139

View more
  4 in total

Review 1.  Significance of psychosocial factors in cardiology: update 2018 : Position paper of the German Cardiac Society.

Authors:  Christian Albus; Christiane Waller; Kurt Fritzsche; Hilka Gunold; Markus Haass; Bettina Hamann; Ingrid Kindermann; Volker Köllner; Boris Leithäuser; Nikolaus Marx; Malte Meesmann; Matthias Michal; Joram Ronel; Martin Scherer; Volker Schrader; Bernhard Schwaab; Cora Stefanie Weber; Christoph Herrmann-Lingen
Journal:  Clin Res Cardiol       Date:  2019-05-10       Impact factor: 5.460

2.  Improvement in health-related quality of life after renal sympathetic denervation in real-world hypertensive patients: 12-month outcomes in the Global SYMPLICITY Registry.

Authors:  Ingrid Kindermann; Sonja Maria Wedegärtner; Felix Mahfoud; Joachim Weil; Nicole Brilakis; Julia Ukena; Sebastian Ewen; Dominik Linz; Martin Fahy; Giuseppe Mancia; Michael Böhm
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-05-07       Impact factor: 3.738

Review 3.  Joint UK societies' 2019 consensus statement on renal denervation.

Authors:  Melvin D Lobo; Andrew S P Sharp; Vikas Kapil; Justin Davies; Mark A de Belder; Trevor Cleveland; Clare Bent; Neil Chapman; Indranil Dasgupta; Terry Levy; Anthony Mathur; Matthew Matson; Manish Saxena; Francesco P Cappuccio
Journal:  Heart       Date:  2019-07-10       Impact factor: 5.994

Review 4.  Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium.

Authors:  David E Kandzari; Felix Mahfoud; Michael A Weber; Raymond Townsend; Gianfranco Parati; Naomi D L Fisher; Melvin D Lobo; Michael Bloch; Michael Böhm; Andrew S P Sharp; Roland E Schmieder; Michel Azizi; Markus P Schlaich; Vasilios Papademetriou; Ajay J Kirtane; Joost Daemen; Atul Pathak; Christian Ukena; Philipp Lurz; Guido Grassi; Martin Myers; Aloke V Finn; Marie-Claude Morice; Roxana Mehran; Peter Jüni; Gregg W Stone; Mitchell W Krucoff; Paul K Whelton; Konstantinos Tsioufis; Donald E Cutlip; Ernest Spitzer
Journal:  Circulation       Date:  2022-03-14       Impact factor: 29.690

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.